Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lowy

Showing results (341-350 of 401) with videos related to

Pageof 41
Sort By:
Ciba Foundation Symposium|January 1, 1993
Cell transformation by ras and regulation of its protein productD R Lowy, M R Johnson, J E DeClue, et al.
Virology|March 31, 2004
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Diana V Pastrana, Christopher B Buck, Yuk-Ying S Pang, et al.
JAMA|August 21, 2007
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trialAllan Hildesheim, Rolando Herrero, Sholom Wacholder, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 13, 2019
A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8<sup>+</sup> Memory T CellsNicolas Çuburu, Rina Kim, Geoffrey C Guittard, et al.
Journal of the National Cancer Institute|September 6, 2001
Re: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancerF X Bosch, N Muñoz, S de Sanjosé, et al.
Journal of Virology|July 1, 1980
Functional organization of the Harvey murine sarcoma virus genomeE H Chang, J M Maryak, C M Wei, et al.
The Lancet. Oncology|June 16, 2022
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine TrialJaimie Z Shing, Shangying Hu, Rolando Herrero, et al.
International Journal of Cancer|December 11, 1996
Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populationsB Nonnenmacher, S Kruger Kjaer, E I Svare, et al.
Virology|July 26, 2006
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particlesLigia A Pinto, Raphael Viscidi, Clayton D Harro, et al.
Virology|May 12, 2005
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Diana V Pastrana, Ratish Gambhira, Christopher B Buck, et al.
Pageof 41

Showing results (341-350 of 401) with videos related to

Sort By:
Pageof 41
Ciba Foundation Symposium|January 1, 1993
Cell transformation by ras and regulation of its protein productD R Lowy, M R Johnson, J E DeClue, et al.
Virology|March 31, 2004
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Diana V Pastrana, Christopher B Buck, Yuk-Ying S Pang, et al.
JAMA|August 21, 2007
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trialAllan Hildesheim, Rolando Herrero, Sholom Wacholder, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 13, 2019
A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8<sup>+</sup> Memory T CellsNicolas Çuburu, Rina Kim, Geoffrey C Guittard, et al.
Journal of the National Cancer Institute|September 6, 2001
Re: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancerF X Bosch, N Muñoz, S de Sanjosé, et al.
Journal of Virology|July 1, 1980
Functional organization of the Harvey murine sarcoma virus genomeE H Chang, J M Maryak, C M Wei, et al.
The Lancet. Oncology|June 16, 2022
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine TrialJaimie Z Shing, Shangying Hu, Rolando Herrero, et al.
International Journal of Cancer|December 11, 1996
Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populationsB Nonnenmacher, S Kruger Kjaer, E I Svare, et al.
Virology|July 26, 2006
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particlesLigia A Pinto, Raphael Viscidi, Clayton D Harro, et al.
Virology|May 12, 2005
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Diana V Pastrana, Ratish Gambhira, Christopher B Buck, et al.
Pageof 41